Walvax Biotechnology Co., Ltd.

300142

CNE100000WN2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
12.47 ^CNY	-2.50%		+1.22%	-46.96%

05-23	Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024	CI
04-26	Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024	MT

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024

May 22, 2024

Walvax Biotechnology Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included) of CNY 0.10000000. Record date is 29 May 2024. Ex-date is 30 May 2024.

Payment date is 30 May 2024.

Latest news about Walvax Biotechnology Co., Ltd.

Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024	05-22	CI
Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024	04-26	MT
Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial	04-25	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
China's drugmakers can't sell mRNA shots but haven't quit yet	04-19	RE
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	04-03	CI
Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.	04-02	CI
Walvax Biotechnology's 2023 Profit Falls 42%	04-02	MT
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023	04-01	CI
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds	04-01	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit	01-26	MT
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook	01-26	MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	01-11	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	01-03	CI
Lanvin Group Chief Executive Joann Cheng Steps Down	12-08	MT
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines	11-08	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%	24/10/23	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	11/10/23	CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia	20/09/23	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Walvax Biotechnology's COVID-19 Vaccine Clinical Trial Results Show Efficacy, Safety	11/07/23	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	03/07/23	CI
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares	26/06/23	MT

Chart Walvax Biotechnology Co., Ltd.

Duration

Period

More charts

Company Profile

Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.

Sector

Pharmaceuticals

Calendar

25/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Walvax Biotechnology Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

12.47 CNY

Average target price

18 CNY

Spread / Average Target

+44.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
WALVAX BIOTECHNOLOGY CO., LTD.	-46.96%	2.75B
CSL LIMITED	+0.75%	92.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.03%	37.9B
BIOGEN INC.	-10.46%	33.73B
UCB	+74.27%	27.98B
BIOMARIN PHARMACEUTICAL INC.	-13.39%	15.86B
INCYTE CORPORATION	-1.08%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.15%	11.67B
ALTEOGEN INC.	+169.04%	10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.19%	10.04B

Biopharmaceuticals